Miraculins Inc.

Miraculins Inc.

July 08, 2010 15:12 ET

Miraculins Announces Grant of Options

WINNIPEG, MANITOBA--(Marketwire - July 8, 2010) - Miraculins Inc. (TSX VENTURE:MOM), a company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, announces today that it has granted an aggregate of 1,850,000 stock options at an exercise price of $0.14 per common share, to the President and CEO, a consultant and certain directors of the Company. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of the grant.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information